Home Compare ARGX.BR vs ZEAL.CO
Stock Comparison · Industry comparison · Biotechnology

argenx vs Zealand Pharma A/S: Which Stock Looks Stronger in 2026?

Zealand Pharma A/S holds the cleaner structural position, with the lead spread across growth and valuation. argenx SE still has the edge on stability, which keeps the comparison from looking entirely one-sided. Both sides have seen trend damage — neither carries a clear market edge right now. With both trends damaged, the structural comparison carries most of the weight here.

The comparison is based on similar long-term financial trajectories, not sector labels.

Updated 2026-04-05

The clearest separation starts in growth, but valuation adds another real layer to the result. The overall score gap is 33 points in favour of Zealand Pharma A/S.

INDUSTRY COMPARISON

Both operate in: Biotechnology

This comparison is based on industry proximity, not on functional trajectory similarity. ARGX.BR and ZEAL.CO share the same industry classification.

For a similarity-based comparison, see how argenx SE and Zealand Pharma A/S each position within their functional peer groups in AssetNext.

Peer-Relative Score
ARGX.BR
argenx SE
51
Peer-Score
Signal qualityHigh
vs
ZEAL.CO
Zealand Pharma A/S
84
Peer-Score
Signal qualityHigh

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

Score differences across key dimensions.

Dimension spread: ARGX.BR vs ZEAL.CO Profitability 53 100 Stability 77 36 Valuation 37 88 Growth 42 100 ARGX.BR ZEAL.CO
Gap Ranking
#1 Growth +58
#2 Valuation +51
#3 Profitability +47
#4 Stability +41
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for ARGX.BR and ZEAL.CO Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer ARGX.BRZEAL.CO Relative valuation Structural strength

Zealand Pharma A/S looks stronger both structurally and on relative valuation.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Growth
Both profiles are strong on growth, but Zealand Pharma A/S leads clearly.
Valuation
On valuation, the gap still runs the same way: Zealand Pharma A/S sits near the top of the group, while argenx SE remains in the weaker half.
Growth — Dominant Gap
ARGX.BR
42
ZEAL.CO
100
Gap+58in favour of ZEAL.CO

Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.

What keeps the gap from being one-sided

Stability still leans toward argenx SE, so the lead is real without reading as one-way.

What this means for the comparison

The lead is built on both growth and valuation — though stability still provides a counterweight.

Explore full peer positioning in AssetNext

Break down the ARGX.BR vs ZEAL.CO comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Other comparisons with conflicting dimension signals

Explore how ARGX.BR and ZEAL.CO each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.